NNC0487-0111 for weight loss in people with obesity and sleep apnoea using airway pressure
Tests NNC0487-0111 against placebo in adults with overweight or obesity and sleep apnoea.
Plain-language title generated from the registry record
Registry title: AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Key facts
- Where
- Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, and Tokyo, JapanSee the 10 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity and moderate-to-severe obstructive sleep apnoea who are treated with positive airway pressure (PAP). People get NNC0487-0111 or placebo as a weekly injection under the skin.
- Age
- 18 years or older
- Sex
- Men and women (sex at birth)
- Disease stage
- Obstructive sleep apnoea diagnosed before screening as moderate-to-severe, with an AHI of 15 or more, and treated with positive airway pressure
- Earlier treatment
- Cannot have had GLP-1 receptor agonist, dual GLP-1/GIP, other GLP-1 based treatment or amylin analogue treatment before screening
- Biomarker or test result
- HbA1c must be below 6.5% (48 mmol/mol) at screening
Main reasons for not taking part
- HbA1c of 6.5% (48 mmol/mol) or higher at screening
- History of type 1 or type 2 diabetes
- Surgery for sleep apnoea planned or done within 90 days before screening
- Significant craniofacial abnormalities that may affect breathing, for example Treacher Collins syndrome or Pierre Robin Sequence
- Treatment with GLP-1 receptor agonists, dual GLP-1/GIP agonists, other GLP-1 based treatment or amylin analogues before screening
Read by machine on 9 November 2026.
Where in Japan
- Fukuoka University Hospital_Respiratory MedicineFukuoka, JapanTaking people
- Chatani NeuroSleep Clinic_NeurologyHiroshima, JapanTaking people
- Kuwamizu Hospital_Internal MedicineKumamoto, JapanTaking people
- Nakamura Clinic_PulmonologyOkinawa, JapanTaking people
- Osaka Kaisei Hospital_Sleep Medical CenterOsaka, JapanTaking people
- KKR Sappro Medical Center_Respiratory MedicineSapporo-shi, Hokkaido, JapanTaking people
- Chutoen General Medical Center_NeurologyShizuoka, JapanTaking people
- Juntendo University Hospital_Cardiovascular Biology And MedicineTokyo, JapanTaking people
- Tokyo Tenshi Hospital_Internal medicineTokyo, JapanTaking people
- Tokyo-Eki Center-building Clinic_Internal MedicineTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07571109EU 2024-520443-16-00
- Record updated
- 7 October 2026
- Original description
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
Inclusion: Male or female (sex at birth); Age 18 years or above at the time of signing informed consent; Previously diagnosed moderate-to-severe OSA with an AHI ≥ 15, as diagnosed with polysomnography (PSG), home sleep apnoea test (HSAT), or other method that meets local guidelines prior to screening.
Exclusion: Any planned or previous surgery within 90 days prior to screening for sleep apnoea, including septoplasty, turbinoplasty, or other ear, nose, and throat surgeries, including tonsillectomy and adenoidectomy; Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records; Significant craniofacial abnormalities that may affect breathing at baseline, for example Treacher Collins syndrome and Pierre Robin Sequence; Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.